What amount sold does 28bio, Inc. report in Form D filings?

The latest linked filings report $12.6M sold across 4 identified offering(s). 2 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was 28bio, Inc.'s most recent SEC filing?

28bio, Inc.'s most recent Form D filing was on 2026-10-29.

How many investors does 28bio, Inc. have?

The most recent Form D filing lists 10 investor(s).

What type of securities does 28bio, Inc. offer?

28bio, Inc.'s SEC Form D filings indicate equity offerings.

28bio, Inc.

CIK: 0001769360·Biotechnology·METAIRIE, LA·Corporation

Reported Sold

$12,649,233

Total Filings

Identified Offerings

Last Filed

Oct 29, 2026

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 2 unlinked amendments excluded.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Oct 29, 2026Form D/A — Amendment

Reported sold: $8,524,945 · Target: $8,524,945

Rule 506(b)·10 investors

Changed: Reported amount sold, Offering target, Reported investors, Sales commissions, Finders fees, Non-accredited investors

Jan 27, 2026Form D/A — Amendment

Reported sold: $6,525,000 · Target: $7,000,000

No verified predecessor available.

Rule 506(b)·8 investors

Jun 24, 2025Form D — New notice

Reported sold: $1,775,000 · Target: $5,000,000

Rule 506(b)·2 investors

Nov 22, 2024Form D — New notice

Reported sold: $3,684,771 · Target: $4,751,652

Rule 506(b)·21 investors

Jun 10, 2021Form D/A — Amendment

Reported sold: $6,056,462 · Target: $6,056,462

Rule 506(b)·12 investors

Changed: Reported amount sold, Offering target, Reported investors

Jun 15, 2020Form D — New notice

Reported sold: $1,965,997 · Target: $3,765,996

Rule 506(b)·7 investors

Mar 5, 2019Form D — New notice

Reported sold: $1,133,000 · Target: $2,500,000

Rule 506(b)·13 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

43%

Latest reported sold across 4 identified offerings

$12,649,233

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

2 unlinked amendments excluded.

Key People

Dale Pfost

Related Person

Appears on 4 filings

Michael Katz

Related Person

Appears on 4 filings

J. Lowry Curley

Related Person

Appears on 3 filings

Michael Moore

Related Person

Appears on 3 filings

Jeffrey Silverman

Related Person

Appears on 3 filings

David Weiner

Related Person

Appears on 2 filings

Alif Saleh

Related Person

Appears on 2 filings

Dale Pfost

Director

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Oct 29, 2026	Amendment	$8,524,945	$8,524,945	10
Jan 27, 2026	Amendment	$7,000,000	$6,525,000	8
Jun 24, 2025	New	$5,000,000	$1,775,000	2
Nov 22, 2024	New	$4,751,652	$3,684,771	21
Jun 10, 2021	Amendment	$6,056,462	$6,056,462	12
Jun 15, 2020	New	$3,765,996	$1,965,997	7
Mar 5, 2019	New	$2,500,000	$1,133,000	13

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Therapeutic Neuromodulation Systems LLC

Biotechnology

Offering target: $5,000,000

Filed Sep 21, 2026